# US 5,700,680 A · Fusion proteins > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,700,680 A - Document ID: US5700680A - Status: Granted - Kind: A - Application number: 08/471,266 - Filed: 1995-06-06 - Granted: 1997-12-23 - Earliest claimed: 1987-02-10 - Assignees: Glaxo Wellcome Inc. - Inventors: Susan Elizabeth Newton; Berwyn Ewart Clarke - Web page: https://patentgrep.com/patent/US5700680A ## CPC - C07K 14/005: from viruses - C12N 15/86: Viral vectors - A61K 2039/5256: {expressing foreign proteins} - C07K 2319/00: Fusion polypeptide - C12N 2710/14143: viral genome or elements thereof as genetic vector - C12N 2710/24143: viral genome or elements thereof as genetic vector - C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract A DNA sequence encoding a fusion protein comprising influenza virus HA, at a site of which normally occupied by a natural antigenic epitope thereof a different antigenic epitope is provided, is incorporated in a vector which is capable of expressing the fusion protein when provided in a eucaryotic host. When in the form of a viral vector such as a recombinant vaccinia virus, the vector can be used as a vaccine. Alternatively, the fusion protein expressed by the host can be recovered and provided as a vaccine. ## Claims ### Claim 1 A DNA sequence encoding a fusion protein which comprises influenza virus haemagglutinin (HA) and, at antigenic site A of HA, a heterologous epitope, wherein all or part of said antigenic site is replaced by said epitope and said protein presents said epitope in a manner recognizable by an immune system. ### Claim 2 (depends on 1) The DNA sequence according to claim 1, wherein said epitope is selected from the group consisting of an epitope of a virus, an epitope of a bacterium and an epitope of a protozoan. ### Claim 3 (depends on 2) The DNA sequence according to claim 2, wherein said epitope is selected from the group consisting of an epitope of foot-and-mouth disease virus, an epitope of poliovirus, an epitope of human rhinovirus and an epitope of hepatitis B virus. ### Claim 4 (depends on 2) The DNA sequence according to claim 2, wherein said epitope is an epitope of Plasmodium falciparum. ### Claim 5 A eucaryotic expression vector comprising a DNA sequence encoding a fusion protein, which protein comprises influenza virus haemagglutinin (HA) and, at antigenic site A of HA, a heterologous epitope, wherein all or part of said antigenic site is replaced by said epitope and said protein presents said epitope in a manner recognizable by an immune system. ### Claim 6 (depends on 5) The vector according to claim 5, wherein said epitope is selected from the group consisting of an epitope of a virus, an epitope of a bacterium and an epitope of a protozoan. ### Claim 7 (depends on 5) The vector according to claim 5, wherein said vector is a viral vector. ### Claim 8 (depends on 6) The vector according to claim 6, wherein said epitope is selected from the group consisting of an epitope of foot-and-mouth disease virus, an epitope of poliovirus, an epitope of human rhinovirus and an epitope of hepatitis B virus. ### Claim 9 (depends on 6) The vector according to claim 6, wherein said epitope is an epitope of Plasmodium falciparum. ### Claim 10 (depends on 7) The vector according to claim 7, wherein said vector is a recombinant vaccinia virus that comprises said DNA sequence. ### Claim 11 A eucaryotic host cell comprising a vector comprising a DNA sequence encoding a fusion protein, which protein comprises influenza virus haemagglutinin (HA) and, at antigenic site A of HA, a heterologous epitope, wherein all or part of said antigenic site is replaced by said epitope and said host cell expresses said fusion protein on the surface thereof and presents said epitope in a manner recognizable by an immune system. ### Claim 12 (depends on 11) The host according to claim 11, wherein said epitope is selected from the group consisting of an epitope of a virus, an epitope of a bacterium and an epitope of a protozoan. ### Claim 13 (depends on 11) The host according to claim 11, wherein said epitope is an epitope of Plasmodium falciparum. ### Claim 14 (depends on 11) The host according to claim 11 wherein said host is a mammalian cell. ### Claim 15 (depends on 12) A host according to claim 12, wherein said epitope is selected from the group consisting of an epitope of foot-and-mouth disease virus, an epitope of poliovirus, an epitope of human rhinovirus and an epitope of hepatitis B virus. ### Claim 16 A eucaryotic plasmid expression vector compatible with a yeast host comprising a DNA sequence encoding a fusion protein, which protein comprises influenza virus haemagglutinin (HA) and, at antigenic site A of HA, a heterologous epitope, wherein all or part of said antigenic site is replaced by said epitope and said protein presents said epitope in a manner recognizable by an immune system. ### Claim 17 A yeast host comprising a vector compatible with said host, comprising a DNA sequence encoding a fusion protein, which protein comprises influenza virus haemagglutinin (HA) and, at antigenic site A of HA, a heterologous epitope, wherein all or part of said antigenic site is replaced by said epitope and said protein presents said epitope in a manner recognizable by an immune system, and wherein said host expresses said fusion protein.